

1 SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis

2  
3 HAT diagnosis by SHERLOCK

4  
5 Núria Sima<sup>1,2</sup>, Annick Dujeancourt-Henry<sup>1</sup>, Blanca Liliana Perlaza<sup>4</sup>, Marie-Noelle Ungeheuer<sup>4</sup>,  
6 Brice Rotureau<sup>2,3</sup>†\* and Lucy Glover<sup>1</sup>†\*.

7  
8 <sup>1</sup> Institut Pasteur, Université de Paris, Trypanosome Molecular Biology Unit, Department of  
9 Parasites and Insect Vectors, Paris, France.

10 <sup>2</sup> Institut Pasteur, Université Paris Sorbonne, Trypanosome Transmission Group, Trypanosome  
11 Cell Biology Unit, INSERM U1201 & Department of Parasites and Insect Vectors, Paris, France.

12 <sup>3</sup> Institut Pasteur of Guinea, Parasitology Unit, Conakry, Guinea.

13 <sup>4</sup> Institut Pasteur, ICAReB platform (Clinical Investigation & Access to Research Bioresources)  
14 of the Center for Translational Science, Paris, France.

15 † Co-last authors

16  
17 \* To whom correspondence should be addressed [lucy.glover@pasteur.fr](mailto:lucy.glover@pasteur.fr), Tel: +33 140613425;  
18 [brice.rotureau@pasteur.fr](mailto:brice.rotureau@pasteur.fr), Tel: +33 140613833.

19  
20 **Keywords:** *Trypanosoma brucei*, HAT, diagnostic, SHERLOCK.

21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 **Abstract**

40

41 Elimination of Human African Trypanosomiasis (HAT) requires highly specific and sensitive  
42 tools for both diagnostic at point of care and epidemiological surveys. We have adapted  
43 SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for the detection of  
44 trypanosome nucleic acids. Our SHERLOCK4HAT diagnostic tool kit, using *7SLRNA*, *TgSGP*  
45 and *SRA* targets, distinguishes between *Trypanosoma brucei* (*T. b.*) *brucei*, *T. b. gambiense* (*g*)  
46 and *T. b. rhodesiense* (*r*) without cross-reactivity and with sensitivity between 0.01 and 0.1  
47 parasite/ $\mu$ L. SHERLOCK4HAT can accurately detect a trypanosome infection in cryo-banked  
48 patient buffy coats, with 85.1% sensitivity and 98.4% specificity for gHAT, and 100% sensitivity  
49 and 94.1% specificity for rHAT. Our SHERLOCK4HAT diagnostic showed 85.6% correlation  
50 with a reference standard qPCR in gHAT patients, 96.2% correlation in rHAT patients,  
51 discriminates between r/gHAT with 100% accuracy and is compatible with lateral flow assay  
52 readout for use at the point of care.

53

54

## 55 Introduction

56 Human African Trypanosomiasis (HAT), or sleeping sickness, is endemic to sub-Saharan  
57 countries and without prompt diagnosis and treatment, is usually fatal (1). It is caused by a tsetse-  
58 borne infection with protist parasites: *Trypanosoma brucei* (*T. b.*) *gambiense* (gHAT), which  
59 represents 85% of the new cases and is endemic to central and western Africa, and *T. b.*  
60 *rhodesiense* (rHAT) which is responsible for the remaining 15% and is found in southern and  
61 eastern Africa. Due to both vector control, mass screening and treatment of those infected, the  
62 number of gHAT cases is decreasing, and has been maintained below 1,000 new gHAT cases /  
63 year since 2018 (2). In this context, gHAT has been included in the WHO roadmap to elimination,  
64 with zero transmission by 2030 (2). Because of the preference of *T. b. rhodesiense* for the animal  
65 reservoir and the scarcity of control tools, the complete elimination of rHAT is not considered to  
66 be feasible.

67 The current diagnostic algorithms for gHAT rely on an initial serological test, followed by a  
68 parasitological confirmation by direct observation under microscope, which is time consuming,  
69 requires trained staff and specialized equipment, and presents a suboptimal diagnostic sensitivity.  
70 The reduction in gHAT cases has brought about new challenges, not least that the positive  
71 predictive value of any diagnostic test diminishes as the disease burden is reduced. This has been  
72 already observed with the gHAT serological tests, the classical Card Agglutination Test for  
73 Trypanosomiasis (CATT) and the more recently developed rapid diagnostic tests (RDTs) (review  
74 in (3, 4)). Moreover, these tests are based on specific surface antigens, which if poorly or not  
75 expressed, can lead to missed diagnoses. No serological diagnostic tools are available for rHAT,  
76 and diagnosis is still based on clinical manifestations and visual detection of parasites by  
77 microscopy. Several molecular amplification tests have been developed for gHAT with promising  
78 results (18SrDNA-PCR, TBR-PCR, Tb177bp-qPCR, 18SrDNA-qPCR, SLRNA RT-qPCR, 18S  
79 RNA RT-qPCR, RIME-LAMP) (review in (3, 4)) but their applications for mass screening are  
80 limited due to cost and required infrastructure. Importantly, diagnosis of gHAT is further  
81 complicated as there is increasing evidence that the traditional parasitological approaches fail to  
82 detect *T. b. gambiense* infections among ‘asymptomatic’ seropositive individuals who are  
83 apparently able to control infection to low levels and / or to maintain extravascular parasites,  
84 especially in the skin, in the absence of detectable blood parasitemia (5). Not only may these  
85 individuals contribute to transmission, but they may potentially go on to develop clinical gHAT  
86 (5–7). Ultimately, specific and high-sensitive tools, suitable for point-of-care (PoC) diagnosis and  
87 / or usable in a high-throughput mode in low-income countries are needed.

88 Adaptation of CRISPR technology towards the development of molecular diagnostics has led to  
89 highly sensitive and specific tools for the detection of *Plasmodium* (8, 9), Zika, Dengue, SARS-  
90 CoV-2, Ebola and *Mycobacterium tuberculosis* to name a few (10). SHERLOCK (for Specific  
91 High-sensitivity Enzymatic Reporter unLOCKing) is a CRISPR-based approach that relies on the  
92 programable collateral nuclease activity of Cas enzymes to identify specific nucleic acid (NA)  
93 sequences in samples (11, 12). Here, we describe the development of a point-of-care applicable,  
94 highly sensitive and specific diagnostic tool that can discriminate between trypanosome species  
95 causing g- and rHAT. Our SHERLOCK4HAT tool kit, meets the current WHO recommendations

96 for gHAT diagnostic, and we show its exquisite sensitivity and specificity using RNA from  
97 cultured parasites, simulated infections and cryo-banked patient samples.

## 98 **Results**

### 99 **Selection of *Trypanosoma* target regions**

100 The SHERLOCK workflow combines isothermal recombinase polymerase amplification (RPA)  
101 with highly specific Cas13-CRISPR RNA target recognition coupled to readout via plate reader  
102 (for mass screening) or lateral flow strip (for PoC diagnosis) (Fig. 1A) (12, 13). To adapt  
103 SHERLOCK for the detection of *T. brucei* sp., we selected gene targets based on the following  
104 criteria (i) genes expressed in the human infective form of the parasites, (ii) *T. brucei* species- or  
105 subspecies-specific, (iii) degree of conservation between different strains and (iv) few to no single  
106 nucleotide polymorphisms (SNPs) (11, 14). We assessed several candidate genes, including the  
107 superoxide dismutase B1 (*SODB1*) gene (Tb927.11.15910), the component of the peptide  
108 recognition particle, *7SLRNA* (Tb927.8.2861), the *T. b. gambiense*-specific glycoprotein gene  
109 (*TgSGP*; FN555988.1) and the *T. b. rhodesiense*-specific serum resistance associated gene (*SRA*;  
110 AF097331). BLAST analysis revealed that the *SODB1* gene sequence is highly conserved  
111 between the *Trypanozoon* subgenus with 99% identity (*T. b. rhodesiense* sequence was not  
112 available) and shared certain degree of homology with *T. cruzi* and *Leishmania donovani* genes  
113 (77.92% and 76.68% identity, respectively) (data file S1). The *7SLRNA* is highly conserved  
114 within the *Trypanozoon* taxa, with 99% identity shared between the *T. brucei* sp., but more distant  
115 to the co-endemic species *T. congolense* and *T. vivax* with 86.31% and 79.77% identity  
116 respectively (data file S1). *TgSGP* gene is specific to Group 1 *T. b. gambiense* and conserved  
117 across isolates in endemic territories (15–17). *TgSGP*-like genes, closely related to a possible  
118 ancestor *VSG* gene (Tb10.v4.0178), have been identified in other *T. brucei* spp., with the 5'  
119 region of the genes particularly conserved (16, 17). *SRA* is specific to *T. b. rhodesiense* and  
120 provides an unbiased identification of the parasite (18–24). Nevertheless, *SRA* is a *VSG*-like gene  
121 (18) and the first 400 bp share 81% identity with a possible ancestor gene present in the *T. b.*  
122 *brucei* genome (Tb927.9.17380) (25). Three *SRA* sequence variants (AF097331, AJ345057,  
123 AJ345057) have been identified from field isolates with homology from 97.9–99.7% (22, 23, 26)  
124 (fig. S1). To develop a pan-*Trypanozoon* SHERLOCK diagnostic, RPA primers and CRISPR  
125 RNA guides (crRNAs) were designed to cover the conserved regions of the *7SLRNA* and *SODB1*  
126 genes in the *Trypanozoon* subgenus, that are distinct to the other trypanosomatids. For a *T. b.*  
127 *gambiense* and *T. b. rhodesiense* specific SHERLOCK diagnostic, guides were designed to the  
128 variable regions of *TgSGP* and *SRA* genes. In an attempt to ensure our tests would be applicable  
129 across a wide range of field isolated strains, identified SNPs were considered and guides were  
130 designed outside of these regions (tables S1 and S2).

### 131 **SHERLOCK distinguishes between the three *T. brucei* subspecies with high sensitivity**

132 We focused on developing a SHERLOCK diagnostic for the two subspecies of *T. brucei* that  
133 cause HAT. We screened several RPA primer pairs and crRNA combinations for each of the  
134 selected target genes (fig. S2 and table S1 and S3). For *7SLRNA* target, 3 RPA amplicons (Ampl)  
135 were combined with 4 crRNA candidates (Ampl 1:crRNAb1-b3, bs, Ampl 2:crRNAb1-b3, Ampl

136 3:crRNA<sub>b1-b3</sub>, bs); for *SODBI* target, 6 RPA amplicons and 15 crRNA candidates were studied  
137 (Ampl 1:crRNA 1.1-1.3, Ampl 2:crRNA 2.1-2.2, Ampl 3:crRNA 3.3, Ampl 4:crRNA 4.1-4.3,  
138 Ampl 5:crRNA 5.1, 5.3, Ampl 6:crRNA 6.1-6.4); 8 RPA amplicons and 23 crRNA were tested  
139 for *TgSGP* (Ampl 1:crRNA 1.1-1.3; Ampl 2:crRNA 2.1-2.3; Ampl 3:crRNA 3.1-3.3, Ampl  
140 4:crRNA 4.1-4.3, Ampl 5:crRNA 5.1, 5.3, Ampl 6:crRNA 6.1-6.3, Ampl 7:crRNA 7.1-7.3, Ampl  
141 8:crRNA 8.1-8.3); and 5 RPA amplicons and 14 crRNA were assessed for *SRA* (Ampl 1:crRNA  
142 1.1-1.3, Ampl 2:crRNA 2.1-2.2, Ampl 4:crRNA 4.1-4.3, Ampl 5:crRNA 5.1-5.3, Ampl 8:crRNA  
143 8.1-8.3) (fig. S2A and table S3). A single RPA amplicon-crRNA combination was selected for  
144 each gene target based on highest signal-to-noise ratio (fig. S2A) and specificity (fig. S2B) when  
145 compared to target recognition in two co-endemic parasite species *Leishmania major* and  
146 *Plasmodium falciparum* and to human embryonic kidney (HEK) T cells, as a representation of the  
147 host. Based on sensitivity and specificity results, we selected single combination of RPA primers  
148 and crRNA sequences for *7SLRNA*, *TgSGP* and *SRA* for all subsequent analyses (Fig.1B and  
149 Table 1). Exquisite specificities were shown for *7SLRNA* as a pan-*Trypanozoon* diagnostic target,  
150 and *TgSGP* and *SRA* as species-specific diagnostic targets for *T. b. gambiense* and *T. b.*  
151 *rhodesiense*, respectively (Fig. 1C). The *7SLRNA* SHERLOCK routinely outperformed the  
152 *SODBI* SHERLOCK, the second pan-*Trypanozoon* target, hence no further experiments were run  
153 with the *SODBI* target. We then wanted to determine the limit of detection (LoD) of each  
154 SHERLOCK reaction. The *SRA* SHERLOCK already showed high sensitivity (Fig. 1D), and did  
155 not require further optimisation. For the *7SLRNA* and *TgSGP* SHERLOCK reactions, we tested  
156 various RPA primer and Magnesium oxalacetate (MgOAc) concentrations (fig. S3), as both can  
157 have a direct impact on the amplification rate, and thus on the amplification efficiency. For all  
158 subsequent analysis, 480 nM of RPA primer and 14 mM MgOAc were used in the *7SLRNA*  
159 SHERLOCK reaction and 240 nM RPA primer and 14 mM MgOAc in the *TgSGP* SHERLOCK  
160 reaction (fig. S3). Using input RNA extracted from cultured parasites, the LoD for the *7SLRNA*  
161 and *TgSGP* targets was determined to be 0.1 parasite/μL, and the LoD for *SRA* target was 0.01  
162 parasite/μL, which falls within the range of parasitemia commonly observed in HAT patients  
163 (Fig. 1D) (27, 28). Using *in vitro* transcribed RNA, the LoD was calculated to be 200 aM (100  
164 molecules/μL) for *7SLRNA* and *TgSGP*, and 20 aM (10 molecules/μL) for *SRA* (fig. S4). This  
165 analytical sensitivity is similar to that reported previously for other molecular diagnostics that are  
166 subgenus specific (29–35) and 10 to 100-fold more sensitive to those reported for subspecies-  
167 specific tests (21, 36, 37).

## 168 **SHERLOCK can be adapted to a PoC diagnostic use**

169 SHERLOCK is amenable to readout by lateral flow assay (LFA) (12). Importantly, using a  
170 polyethylene glycol (PEG)-based CRISPR-optimized buffer (provided by Milenia Biotec), we  
171 were able to detect the *7SLRNA*, *TgSGP* and *SRA* SHERLOCK targets with the same respective  
172 sensitivities as with the fluorescent readout, but with a reduced background signal as compared to  
173 the commercially available LFA buffers, thereby reducing the ambiguity of the readout (Figs. 1E  
174 and S5). Our SHERLOCK4HAT diagnostic kit is therefore compatible with use at the PoC. To  
175 further optimize SHERLOCK4HAT for PoC use as a one-tube reaction (8, 38), we focussed on  
176 the *7SLRNA* target and modified the reaction components and conditions (fig. S6). Given that the  
177 reverse-transcriptase (RT) and Cas13 activities have different temperature preferences, we

178 evaluated the performance of one-tube reactions at temperatures from 37°C to 42°C, and found  
179 that reactions at 37°C had higher signal with reduced sample-to-result time (fig. S6A). An  
180 additional consideration for the development of a PoC diagnosis for use in low-income countries  
181 is affordability. We therefore tested three RT enzymes from different manufacturers and selected  
182 ProtoScript II (NEB) as the most cost-effective reaction with a cost of 2.5 € / reaction (fig. S6B).  
183 Given that Cas13a has uridine-cleavage preference (12, 39), we compared RNase Alert with a  
184 6U-FAM reporter. The signal intensity obtained with the 6U-FAM reporter was lower and was  
185 more prone to spontaneous degradation, as seen with the non-template control reaction (fig. S6C).  
186 Thus, we selected RNase Alert as a reporter for an optimized one-tube SHERLOCK diagnostic  
187 and used 8 µL of input material (fig. S6D). With these improvements, the *7SLRNA* one-tube  
188 SHERLOCK reaction had similar sensitivity than the two-step reaction and detected 1 parasite/µL  
189 in less than 1 h (Fig. 1, F and G).

### 190 **The SHERLOCK4HAT diagnostic kit can accurately detect a trypanosome infection across** 191 **multiple regions and over extended periods of time**

192 Genetic variability between field isolates can potentially lead to false negatives with molecular  
193 diagnostic. Therefore, the development of a robust diagnostic hinges upon the ability to detect all  
194 parasite strains or variants. To demonstrate the robust specificity of our SHERLOCK4HAT  
195 diagnostic kit, we analyzed total RNAs from 57 *Trypanozoon* strains, isolated from their host over  
196 the course of 50 years and maintained at the Institute of Tropical Medicine (ITM, Antwerp,  
197 Belgium) (40) (table S4). Using our two-step SHERLOCK assay, all samples were positive for  
198 *7SLRNA*, confirming *7SLRNA* SHERLOCK as a pan-*Trypanozoon* diagnostic and  
199 epidemiological tool (Fig. 2 and table S4). Within this set, the 46 *T. b. gambiense* Group 1  
200 mammalian stage isolates tested positive for *TgSGP*, and 3 out of 4 *T. b. gambiense* Group 1  
201 insect stage isolates were negative, as expected since *TgSGP* is only expressed in the mammalian  
202 stage of the parasite (15). The single *T. b. gambiense* Group 1 insect stage isolate  
203 (MHOM/CI/91/SIQUE1623) that was positive for *TgSGP*, may have retained low level  
204 expression of the gene. The 7 non-Group 1 *T. b. gambiense* strains tested negative for *TgSGP*,  
205 including the *T. b. gambiense* Group 2 sample (Fig. 2, and table S4), thus confirming the  
206 diagnostic specificity of the *TgSGP* SHERLOCK for *T. b. gambiense* Group 1. The two *T. b.*  
207 *rhodesiense* strains included in the collection were positive for *SRA*, and 54 of the 55 non-*T. b.*  
208 *rhodesiense* strains tested negative for *SRA* (Fig. 2 and table S4). A single isolate, AnTat 22.1,  
209 classified as *T. b. gambiense* Group 1 was positive for both *TgSGP* SHERLOCK and *SRA*  
210 SHERLOCK (table S4). Sequence analysis showed that the *SRA* SHERLOCK target amplicon  
211 shared 83.3% identity with a *VSG* (Tbb1125VSG-4336, accession number: KX700900) that was  
212 expressed in this sample (fig. S7A). There are 7 nucleotide mismatches between the *SRA* guide  
213 and the homologous region in the *VSG* sequence (fig. S7B), and this is the most likely source of  
214 the cross-reactivity. In spite of the 1.8% cross-reactivity observed with the *SRA* SHERLOCK  
215 within the group of samples analyzed, 100% of the strains were detected with the corresponding  
216 test, confirming the use of *TgSGP* SHERLOCK and *SRA* SHERLOCK for diagnosis across  
217 endemic regions.

### 218 **SHERLOCK4HAT detects trypanosomes in dried blood spots, whole blood and buffy coat**

219 There is a critical need for highly sensitive and specific molecular detection tools that can be use  
220 in a high-throughput format in the context of gHAT post-elimination phase. Adapted strategies  
221 will be adopted to monitor for potential residual transmission and these tests will be performed in  
222 regional reference centres. Methods to capture individual samples, such as dried blood spots  
223 (DBSs) would allow easy collection in the field and safe transport and storage back to a lab.  
224 SHERLOCK can detect both DNA and RNA, therefore, working with total nucleic acid (TNA)  
225 instead of RNA alone can increase the sensitivity. However, for use as a test of cure it is  
226 important to work with RNA only, since trypanosome DNA has been detected in the host up to 2  
227 years after cure (35). To optimize the 7SLRNA SHERLOCK for epidemiological surveys, we  
228 compared three methods of TNA extraction from DBS using non-infected sheep blood spiked  
229 with cultured *T. brucei* parasites spotted on Whatman 903<sup>TM</sup> Cards. Our 7SLRNA SHERLOCK  
230 was able to detect 100 parasites/ $\mu$ L using a RNeasy kit (Qiagen) and 10 parasites/ $\mu$ L with the  
231 NucleoSpin Triprep kit (Macherey-Nagel) (fig. S8A). We saw consistently greater sensitivity with  
232 the NucleoSpin Triprep kit, and therefore used it for subsequent extractions from DBSs. Mass  
233 screening campaigns are expected to result in a high volume of samples that require subsequent  
234 processing, thus, an automated system that minimizes the hands-on time in the extraction process  
235 and the cross-contamination between samples is preferred. We compared the performance of two  
236 different kits from the automated, paramagnetic beads-based system Maxwell RSC (Promega)  
237 and the manual column-based system from Qiagen (fig. S8, B and C). Maxwell RSC DNA blood  
238 kit was more efficient than Maxwell RSC RNA kit for TNA extraction using simulated infected  
239 samples and showed no cross-contamination, in contrast to the manual column-base kit (fig. S8, B  
240 and C). Using simulated human infections (un-infected human blood spiked with *T. brucei*  
241 parasites), we compared the performance of the 7SLRNA SHERLOCK using DBS, whole blood  
242 and buffy coat. 7SLRNA SHERLOCK detected trypanosome TNAs equivalent to 1 parasite/ $\mu$ L in  
243 the three types of samples (Fig. 3A), which is in line with the analytical sensitivity reported  
244 previously with the M18S-qPCR in DBS (31). To determine the 7SLRNA SHERLOCK analytical  
245 sensitivity, we analyzed 3 independent dilution series of simulated infections in whole blood and  
246 buffy coat samples and estimated the LoD to be the lowest concentration where 3 out of 3  
247 samples tested positive (Fig. 3, B and D). Here, the resulting analytical sensitivity was determined  
248 to be 10 parasites/ $\mu$ L in whole blood and 1 parasite/ $\mu$ L in buffy coat. This is consistent with the  
249 increased sensitivity seen with the mini-anion exchange centrifugation technique (mAECT) when  
250 buffy coat is analyzed instead of whole blood (27). We further resolved the analytical sensitivity  
251 of the 7SLRNA SHERLOCK with buffy coat by analysing 20 replicates of simulated infected  
252 samples at 0.66X, 1X or 1.5X a 1 parasite/ $\mu$ L parasitemia. We confirmed the 7SLRNA  
253 SHERLOCK buffy coat LoD to be 1 parasite/ $\mu$ L in 95% of the samples detected (Fig. 3, C and  
254 D). Further improvement of the extraction methods will be required to increase the analytical  
255 sensitivity, since the LoD of SHERLOCK tests with RNA from cultured parasites was more  
256 sensitive (Fig. 1D).

### 257 **Validation of the SHERLOCK4HAT diagnostic kit using clinical samples**

258 To validate SHERLOCK4HAT as a diagnostic tool kit, we used samples obtained from the WHO  
259 HAT specimen biobank (41): 98 buffy coat samples from patients with confirmed gHAT; 48  
260 buffy coat samples from gHAT endemic regions, but negative for gHAT, to act as controls; 19

261 buffy coat samples from patients with confirmed rHAT, and 20 buffy coat samples from rHAT  
262 endemic regions, but negative for rHAT, as further negative controls. Additionally, we analyzed  
263 14 buffy coat samples from un-infected donors from non-endemic regions. As a positive control  
264 for TNA extraction to validate negative SHERLOCK results in clinical samples, i.e. to ensure that  
265 no SHERLOCK inhibitors were remaining in the sample, we designed an additional SHERLOCK  
266 assay that targeted the human *RNase P* gene and validated its performance using RNA from  
267 cultured human cells and parasites (fig. S9). All samples were maintained at -80°C from  
268 collection until delivery by the WHO HAT specimen biobank, and all the samples tested here  
269 were more than 10 years old and stored without any preservative (41). Therefore, the likelihood of  
270 TNA deterioration was high, especially for RNA. As an additional control, we ran a *Tb177 bp*  
271 *repeat* qPCR (32) in parallel. Trypanosome DNA was detected by qPCR in 47 out of 98  
272 confirmed gHAT samples, suggesting deterioration of the TNAs in most of the samples (Fig. 4, A  
273 and B and data file S2). Notably, the *7SLRNA* SHERLOCK detected 55 out of 98 confirmed  
274 gHAT samples, showing a higher sensitivity as compared to the reference qPCR test. The  
275 concordance between the two assays was 85.6%, with 40 out of 47 qPCR positive samples and 97  
276 out of 113 qPCR negative samples, positive and negative for SHERLOCK respectively (Fig. 4, A  
277 and B and data file S2). Importantly, 15 of the 16 qPCR negative samples that tested positive for  
278 SHERLOCK were part of the originally confirmed gHAT cohort, revealing our SHERLOCK  
279 diagnostic to be more sensitive than the qPCR test (Fig. 4, A and B and data file S2). None of the  
280 gHAT endemic negative control samples tested positive, and one out of 14 non-endemic negative  
281 control samples was positive using the *7SLRNA* SHERLOCK with an overall specificity of  
282 98.4%. The sensitivity of the *7SLRNA* SHERLOCK was 85.1 % for gHAT, based on the qPCR  
283 positive samples (Fig. 4B). The *TgSGP* SHERLOCK detected 42.5% of the qPCR positive  
284 samples with 88.7% specificity (data file S2 and table S5). These differences in sensitivity  
285 between the spp-specific and the pan-*Trypanozoon* SHERLOCK are most probably due to a  
286 selective degradation of the target RNAs. All 19 confirmed rHAT patient samples tested positive  
287 for *7SLRNA* SHERLOCK with 100% sensitivity and 94.1% specificity (Fig. 4, C and D and data  
288 file S2). To note, the impact of TNA deterioration in these samples may be lower due to the  
289 higher parasitemia in *T. b. rhodesiense* infections (1), seen here by the lower qPCR Ct values in  
290 rHAT samples compared to those in gHAT samples (Fig. 4, A and C and data file S2). The *SRA*  
291 SHERLOCK detected 79% of the qPCR positive samples with 100% specificity (data file S2 and  
292 table S5). The combination of results from the *7SLRNA*, *TgSGP* and *SRA* SHERLOCK  
293 diagnostics suggests an increased sensitivity of the single tests, but slightly reduced specificity  
294 (Fig. 4, B and D and table S5). No correlation between the stages of the disease and the qPCR Ct  
295 values or the SHERLOCK fluorescence readouts in gHAT patients was observed (Fig. 4A and  
296 data file S2). Results of the 19 confirmed rHAT samples with *TgSGP* SHERLOCK were  
297 negative. Likewise, 20 selected confirmed gHAT samples were all negative when run using the  
298 *SRA* SHERLOCK diagnosis protocol (Fig. 4E). Thus, the *TgSGP* and *SRA* SHERLOCK in patient  
299 samples accurately discriminate between *T. b. gambiense* and *T. b. rhodesiense* infections.

## 300 Discussion

301 Here we described the development of a new molecular detection tool for HAT diagnosis adapted  
302 for use at a PoC and for HAT epidemiological surveillance. Our SHERLOCK4HAT diagnostic



303 can distinguish between the three *T. brucei* subspecies using a pan-*Trypanozoon*, *gambiense*-  
304 specific, or *rhodesiense*-specific targets. Although our subspecies-specific targets use *TgSGP* and  
305 *SRA*, which are related to *VSG* genes, we do not see cross reactivity. In fact, in spite of the degree  
306 of DNA sequence homology shared between *SRA* and *VSG* variants, we saw no false positives,  
307 confirming that the selected target meets the specificity requirements for rHAT diagnosis.

308 As an RNA based diagnostic, SHERLOCK4HAT is a highly sensitive detection method for on-  
309 going infections with a simple set up. We show that the analytical sensitivity of  
310 SHERLOCK4HAT for the *Trypanozoon* target is 0.1 parasite/ $\mu$ L (100 parasites/mL), which is  
311 comparable to several molecular techniques for detection of *Trypanozoon* taxa (TBR-PCR/qPCR  
312 and 18S-PCR, 50-100 parasites/mL). However, implementation of these techniques is limited by  
313 the need for sophisticated equipment (29, 31, 32, 42). An additional advantage of  
314 SHERLOCK4HAT is the single temperature isothermal RPA amplification coupled to a Cas13  
315 detection, making our method more adapted to the low-income countries where the disease is  
316 endemic. Other isothermal approaches have been developed with similar sensitivities to  
317 SHERLOCK (LAMP-100 parasites/mL, NASBA-10 parasites/mL) (43, 44), but significant  
318 infrastructure costs have limited their implementation in control programs. Our subspecies-  
319 specific SHERLOCK4HAT diagnostics using a *TgSGP* or *SRA* target are 10 to 100-fold more  
320 sensitive than that the current subspecies-specific diagnostics using PCR/qPCR (21, 36, 45) and  
321 show no overlap between the signal in positive and negative samples, resolving any ambiguity  
322 seen in PCR and qPCR. In fact, our results indicated that SHERLOCK4HAT can unequivocally  
323 discriminate between *TgSGP* and *SRA*, and therefore diagnose of *T. b. gambiense* and *T. b.*  
324 *rhodesiense* infections.

325 The current gHAT field-applicable diagnostic algorithms are based on antibody detection in  
326 patient blood (CATT and RDTs) with confirmation of seropositive cases by parasitological  
327 observation (1, 4). These methods present some limitations: (i) false-negative results if the *VSG*  
328 variants detected by the test are poorly or not expressed (46), (ii) reduced specificity (1, 4), and  
329 (iii) relatively high cost (RDTs), significant workload (CATT on serial plasma dilution, time at  
330 microscope) and need for specialized staff and equipment (especially for parasitological  
331 confirmation). For rHAT, no field-applicable diagnostic methods exist. SHERLOCK4HAT  
332 overcomes these limitations. We have shown that SHERLOCK4HAT detection is not limited by  
333 geography or time after sampling, it is easy to set up, does not require sophisticated equipment  
334 and it is adapted for high-throughput applications (fluorescence readout) or individual testing  
335 (LFA), making it versatile for both surveillance at reference centers and PoC testing. The  
336 SHERLOCK4HAT diagnostic can be run in 1 h 30 min for a one-step reaction (at 4.5 € if coupled  
337 to a commercial LFA), or 2 h 30 min for a two-step reaction (at 2.8 €), and these costs would be  
338 notably reduced with an in-house manufactured strip for LFA.

339 One limitation for SHERLOCK4HAT, as for any molecular diagnostic method, is the NA  
340 extraction step. Several extraction methods coupled to a CRISPR-based diagnostic reaction have  
341 been published (8, 47, 48), but remained to be tested in the context of HAT diagnostics. For high-  
342 throughput surveillance using SHERLOCK4HAT, automated NA extraction systems can be  
343 implemented with higher reproducibility, reduced hand-on time and no cross-contamination.  
344 Manual extraction methods, although more time consuming, showed an increased analytical

345 sensitivity which is consistent with previous studies (49). As an RNA-based diagnostic,  
346 SHERLCOCK is limited by the increased sensitivity of RNA to nuclease degradation, which can  
347 affect the sensitivity of the test if the clinical specimens are not stored properly. Nucleic acid  
348 stabilization buffers or Flinders Technology Associates (FTA) cards to transport and store the  
349 samples can be used to attenuate these limitations. It should be noted that RNA is a better  
350 indicator of active infections than DNA (35), making SHERLOCK4HAT a valuable tool for  
351 assessing treatment outcome.

352 The bio-banked clinical samples used here to validate SHERLOCK4HAT did not allow proper  
353 analysis of sensitivity for gHAT patients. 44% of confirmed gHAT patient samples were negative  
354 with SHERLOCK, and 53% were negative using standard qPCR analysis. The discrepancy  
355 between our results compared to the original in-field diagnostic is most probably due to the  
356 deterioration of the NA in these samples, that were stored at -80°C for more than 10 years without  
357 preservative (41). Low parasitemia is typical in gHAT infections, thus any NA degradation could  
358 have a dramatic effect on detection using molecular techniques. *T. b. rhodesiense* infections have  
359 higher parasitemia, hence deterioration of NA in the samples might have a lower impact in the  
360 diagnostic sensitivity, which is evident given the robust sensitivity using rHAT SHERLOCK. The  
361 lower sensitivity observed with the *TgSGP* target (42.5%) could be attributed to a selective  
362 degradation of the target RNA and / or to a differential expression of the *TgSGP* gene in these  
363 samples, since the analytical sensitivity of SHERLOCK for *7SLRNA* and *TgSGP* was similar.  
364 From the 62 negative control samples, 7 tested positive for *TgSGP* compared to 1 or 0 for  
365 *7SLRNA* SHERLOCK or qPCR, respectively. This reduced specificity needs to be interrogated  
366 further.

367 As we move towards the elimination phase of gHAT, if not to the post-elimination phase in  
368 several countries, SHERLOCK4HAT is a viable alternative to currently used diagnostics at the  
369 PoC. Optimization of the one-pot reaction to meet the sensitivity requirements for HAT diagnosis,  
370 lyophilization of the reaction components and field-friendly NA extraction methods will be  
371 required before large-scale deployment. Sensitivity could also be improved using a combination  
372 of *7SLRNA*, *TgSGP* and *SRA* targets in a multiplex SHERLOCK4HAT diagnostic kit that would  
373 allow the specific detection of the three subspecies of *T. brucei* at the same time in a single  
374 reaction, thereby reducing the full diagnostic cost and making the technology more adapted for  
375 horizontal epidemiological studies, including in animal reservoirs. In total, SHERLOCK4HAT  
376 provides a readily adaptable diagnostic method for HAT allowing for PoC diagnosis, mass  
377 screening and epidemiological surveillance.

## 378 **Materials and Methods**

### 379 **LwCas13a protein expression and purification**

380 Plasmid pC013-Twinstrep-SUMO-huLwCas13a (Addgene plasmid # 90097) (11) was used to  
381 express LwCas13a in *Escherichia coli* Rosseta™ 2(DE3) pLySs competent cells. Cell pellet was  
382 lysed with supplemented lysis buffer (20 mM Tris-HCl pH8.0, 500 mM NaCl, 1 mM DTT, 100  
383 mg lysozyme, 200U Deoxyribonuclease I) and LwCas13a protein was purified from the cleared  
384 supernatant as described in (13) (fig. S10).

## 385 **Target selection and crRNA and RPA primer design**

386 Target genes were selected as either unique or based on their conservation between *Trypanosoma*  
387 spp using literature and publicly available data from TriTrypDB  
388 (<https://tritrypdb.org/tritrypdb/app>). Candidate genes were aligned using BLAST with the  
389 Trypanosomatidae (taxid:5654) nucleotide collection database from the National Center for  
390 Biotechnology Information (NCBI). Alignments to ensure conservation of targets across the  
391 *Trypanozoon* subgenus or exclusivity between *T. brucei* subspecies was performed using Clustal  
392 Omega. Data available in TriTrypDB was used to identify SNPs found in different field isolates  
393 in the target genes *7SLRNA*, *SODBI* and *TgSGP* (50). To identify the SNPs in the *SRA* gene, the  
394 sequence variants AF097331, AJ345057, AJ345057 (22, 26) were aligned using Clustal Omega  
395 and visualized in Jalview 2.11.1. RPA primers and crRNAs were designed to cover the conserved  
396 regions of the selected genes and outside of regions containing single nucleotide polymorphisms  
397 (SNPs). BLAST analysis with the nucleotide collection of all available genomes was performed  
398 to ensure RPA primers and crRNAs specific alignment. A 5' T7 RNA polymerase promoter  
399 sequence (5'GAAATTAATACGACTCACTATAGGG) overhang was added to the RPA forward  
400 primers for *in vitro* transcription (IVT) during SHERLOCK reaction. The amplicons generated  
401 during RPA reactions are between 130-160 nt length. We used a 28 nt crRNA spacer for all  
402 guides in this study except for cr7SLbs which is 26 nt. The spacer sequence is joined to a 5' direct  
403 repeat (DR) to generate the complete crRNA. To facilitate amplification from DNA templates a  
404 T7 RNA polymerase promoter sequence was added upstream of the crRNA (spacer + DR + T7  
405 promoter 5'>3'). RPA primer, crRNA and DNA IVT template sequences are detailed in  
406 supplementary table 1. SNPs identified for each target gene are included in supplementary table 2.

## 407 **Target RNA and crRNA synthesis and purification**

408 To produce the crRNA's, DNA IVT templates and T7-3G oligonucleotide were purchased from  
409 ThermoFisher. crRNAs were synthesized as described in (13) with the following modifications.  
410 DNA IVT template (10 µM) and T7-3G oligonucleotide (10 µM) were annealed in standard Taq  
411 buffer (1x) by performing a 5-minute denaturation, followed by slow cooling (ramp rate was  
412 adjusted to 0.13°C/s) of the reaction to 4°C in a PCR thermocycler (BioRad). IVT was performed  
413 using the HiScribe™ T7 Quick High Yield RNA Synthesis Kit (NEB E2050S), where 10 µL of  
414 annealed reaction were mixed with 10 µL of NTP buffer mix, 2 µL of T7 RNA polymerase mix  
415 and 17 µL of RNase free water. The reaction was incubated for 6 hours at 37°C followed by 15  
416 minutes of DNase I digestion to remove DNA template. Purification of crRNA was done with  
417 Agencourt RNAClean XP beads following the manufacturer's protocol and crRNA concentration  
418 was adjusted to 300 ng/µL. Urea Poly-Acrylamid Gel Electrophoresis were used to confirm the  
419 purity and correct size of crRNAs.

420 120 ng of RNA from *T. b. gambiense* ELIANE strain for *TgSGP* or 40 ng of RNA from *T. b.*  
421 *rhodesiense* EATRO strain for *SRA* RNA production were retro-transcribed using pT19  
422 oligonucleotide and SuperScript IV Retro Transcriptase (Thermo Fisher) following standard  
423 protocols. cDNAs were purified with Ampure XP (A63880) following manufacturer instructions  
424 and eluted in 30 µL of nuclease free water. *TgSGP* and *SRA* were amplified from 5 µL of cDNA,

425 using TgSGP-FL-F and TgSGP-FL-R primers or SRA-FL-F and SRA-FL-R primers,  
426 respectively. For 7SLRNA production, the 7SLRNA gene was amplified from 120 ng of *T. b.*  
427 *brucei* Lister 427 genomic DNA, using 7SLb-UP-F.6 and 7SLb-FL-R primers. The PCR  
428 amplification reaction was as follows: 0.2 mM dNTPs, 0.5  $\mu$ M of each primer, 5  $\mu$ L of DNA,  
429 0.75  $\mu$ L of DMSO, 0.5  $\mu$ L of Phusion DNA polymerase in HF buffer 1X in a 25  $\mu$ L final volume  
430 and was run according to standard PCR settings. A T7 RNA polymerase promoter sequence  
431 overhang was included in each forward primer for *in vitro* transcription. IVT of the amplified  
432 genes was performed using the HiScribe™ T7 Quick High Yield RNA Synthesis Kit following  
433 manufacturer's instructions and the reaction incubated for 3 hours at 37°C followed by 15  
434 minutes of DNaseI digestion. The single stranded RNA was purified using Agencourt RNAClean  
435 XP beads following the manufacturer's protocol. *In vitro* transcribed RNAs were sequenced and  
436 Urea Poly-Acrylamid Gel Electrophoresis were used to confirm the purity and correct size of the  
437 target RNAs. Primer sequences used in this section are specified in supplementary table 6.

### 438 **RNA isolation from cultured parasites**

439 *T. b. brucei* Lister 427 bloodstream stage cells were cultured in HMI-11 medium at 37.4°C with  
440 5% CO<sub>2</sub>. RNA was harvested at 1x 10<sup>6</sup> cell/mL. *T. b. gambiense* ELIANE and *T. b. rhodesiense*  
441 EATRO cell pellets were a gift from Annette MacLeod and *L. major* cells were a gift from Gerald  
442 Spaeth. Total RNA from *T. b. brucei* Lister 427, *T. b. gambiense* ELIANE strain, *T. b.*  
443 *rhodesiense* EATRO strain, *L. major* and Human embryonic kidney (HEK) 293T cells, was  
444 extracted with the RNeasy Mini kit (Qiagen).

### 445 **Simulated samples and total nucleic acid (TNA) extraction from blood, buffy coat and dry** 446 **blood spots (DBS)**

447 Blood from healthy human donors was provided by ICAReB platform (Clinical Investigation &  
448 Access to Research Bioresources) in the Center for Translational Science, at the Institut Pasteur  
449 (Paris) (51). All participants gave written informed consent in the frame of the healthy volunteers  
450 Diamicoll cohort (Clinical trials NCT 03912246) after approval of the CPP Ile-de-France I  
451 Ethics Committee (2009, April 30th). Whole blood was extracted in BD Vacutainer™ Glass ACD  
452 Solution Tubes and immediately processed. To determine the performance of 7SLRNA  
453 SHERLOCK in whole blood, buffy coat and DBS, 2x10<sup>5</sup> *T. b. brucei* Lister 427 parasites were  
454 spiked into 20 mL of human blood followed by 1:10 dilution to simulate parasitemia of 10 and 1  
455 parasites/ $\mu$ L. Nine drops of 50  $\mu$ L of each dilution of the simulated infected blood and non-  
456 infected blood were dried on Whatman 903™ Cards and stored at RT for 24 hours until  
457 processed. Three tubes of 500  $\mu$ L of whole blood were snap-frozen and stored at -80°C for 72  
458 hours. To obtain the buffy coat, 12 mL of each simulated infected blood dilution and non-infected  
459 blood were centrifuged at 1800 g for 10 minutes without brake, at 4°C to prevent RNA  
460 degradation. Three tubes of 125  $\mu$ L of buffy coat for each dilution were snap-frozen and stored at  
461 -80°C for 72 hours. TNA extraction from DBS was performed with the Nucleospin Triprep kit  
462 (Macherey-Nagel). For that, 6 x 6 mm punches were incubated with 350  $\mu$ L of RP1 buffer and 3.5  
463  $\mu$ L of  $\beta$ -mercaptoethanol at 37°C for 30 minutes in agitation (1000 rpm). The instructions from  
464 the manufacturer were followed from this step onwards. DNA and RNA were eluted together in

465 40 µL of nuclease free water. TNAs from whole blood and buffy coat simulated samples was  
466 conducted with Maxwell RSC DNA blood kit (PROMEGA AS1400). The samples were pre-  
467 processed with 300 µL of lysis buffer and 30 µL of Proteinase K solution, vortexed for 10  
468 seconds and incubated at 56°C for 20 minutes. The volume was transferred to the Maxwell  
469 Cartridge and the kit protocol was run in the automated Maxwell RSC system. TNAs were eluted  
470 in 60 µL of elution buffer. Extractions for each dilution and type of sample were done in  
471 triplicate.

#### 472 **Determination of analytical sensitivity**

473 To determine the analytical sensitivity of 7SLRNA SHERLOCK limiting dilutions of *T. b. brucei*  
474 Lister 427 parasites were spiked into un-infected human blood. TNAs were extracted from whole  
475 blood and buffy coat with Maxwell RSC DNA blood kit as detailed above. Three replicates of  
476 each dilution were assessed by SHERLOCK and the estimated LoD was determined as the lowest  
477 concentration where 3 out of 3 replicates were positive. The analytical sensitivity was confirmed  
478 in buffy coat by using 20 replicates of 0.66X, 1X and 1.5X the estimated LoD concentration. The  
479 analytical sensitivity was determined as the concentration where 95% of the samples gave  
480 positive results.

#### 481 **Optimization of TNA extraction methods**

482 To compare different TNA extraction methods from DBS, sheep blood was spiked with *T. b.*  
483 *brucei* Lister 427 parasites at limiting dilutions (1000-1 parasites/µL). Drops of 50 µL were dried  
484 into Whatman 903<sup>TM</sup> Cards and stored at RT for 24 hours. For TNA extraction with RNeasy mini  
485 and micro kits (Qiagen) 3 x 6 mm punches were resuspended with 370 µL of RLT buffer with 3.7  
486 µL of β-mercaptoethanol and incubated at 37°C for 30 minutes with agitation (1000 rpm). The  
487 punches and liquid were transferred into a QIAshredder column and spun at maxim speed for 1  
488 minute. The homogenized sample was then processed according to manufacturer's instructions  
489 without DNaseI digestion. DNA and RNA were eluted in the same fraction with 10 µL (RNeasy  
490 micro kit) or 30 µL (RNeasy mini kit) of nuclease-free water. For TNA extraction with the  
491 Nucleospin Triprep kit (Macherey-Nagel) 3 x 6 mm punches were resuspended with 350 µL of  
492 RP1 buffer with 3.5 µL of β-mercaptoethanol and incubated at 37°C for 30 minutes in agitation  
493 (1000 rpm). The instructions from the manufacturer were followed from this step onwards and  
494 DNA and RNA were eluted together in 40 µL of nuclease free water. Maxwell RSC DNA blood  
495 kit (AS1400), Maxwell RSC SimplyRNA blood kit (AS1380) and RNeasy mini kit (Qiagen) were  
496 used to extract TNA from 250 µL or 125 µL of human buffy coat spiked with limiting dilutions of  
497 *T. b. brucei* Lister 427 parasites.

#### 498 **Field isolated samples**

499 The RNA used in this study was derived from 57 field isolates representing different  
500 *Trypanosoma* species, subspecies and strains. The collection contained 50 *T. b. gambiense* group  
501 1 (46 bloodstream forms + 4 insect forms), 1 *T. b. gambiense* group 2, 2 *T. b. rhodesiense*, 1 *T. b.*  
502 *brucei*, 1 *T. equiperdum* and 2 *T. evansi* strains or clones. They were kindly provided by Nick

503 Van Reet and Philippe Büscher (Institute of Tropical Medicine [ITM], Antwerp, Belgium) (40).  
504 The RNA was kept at -80 and the concentration normalized to 5 ng/μL. Three microliters of input  
505 material were used for each SHERLOCK analysis.

## 506 **Clinical samples**

507 Clinical samples in this study were obtained from the WHO HAT Specimen biobank (41). They  
508 included buffy coats from 48 individuals living in *T. b. gambiense* endemic areas who were  
509 negative for gHAT by serology and parasitology, 50 patients with confirmed gHAT at stage 1, 48  
510 patients with confirmed gHAT at stage 2, 20 individuals living in *T. b. rhodesiense* endemic areas  
511 who were negative for rHAT by serology and parasitology and 19 patients with confirmed rHAT  
512 at stage 2. TNA were extracted from 125 μL of sample using the Maxwell RSC Blood DNA kit as  
513 detailed above. The material was eluted in 50 μL of elution buffer.

## 514 **SHERLOCK two-step reaction**

515 For the isothermal amplification step, TwistAmp Basic kit (TwistDx) was used according to  
516 manufacturer's instructions with the following modifications. For each reaction, 3 μL of input  
517 total nucleic acids (TNA) were incubated with 480 nM of each RPA primer (240 nM for *TgSGP*  
518 RPA primers), Reaction buffer 1X, 2.2 U of Transcriptor (Roche), 1.5 U of Murine RNase  
519 inhibitor (NEB) and 14 mM MgOAc and 0.22 pellet of TwistAmp Basic kit, in a final volume of  
520 11 μL. Reaction condition were optimized using different RPA primer concentrations (120, 240  
521 or 480 nM) and MgOAc concentrations (14, 22 or 30 mM). The reactions were run using Hard-  
522 shell thin wall 96 well PCR Plates, sealed with Microseal 'F' Foil Seals (BioRad). Plates were  
523 incubated in a heating block set to 42°C with thermoregulated lid. After a 5 minutes incubation,  
524 the plates were agitated for 15 seconds and the incubation resumed for 40 min. For the LwCas13a  
525 detection step, 1 μL of the previous reaction was incubated with 20 mM HEPES pH 6.5, 9 mM  
526 MgCl<sub>2</sub>, 1 mM rNTP mix (NEB), 126 ng of LwCas13a, 2 U of Murine RNase inhibitor (NEB), 25  
527 U of NxGen T7 RNA Polymerase (Biosearch technology), 10 ng of crRNA and 125 nM of  
528 RNaseAlert probe V2 (Invitrogen) in a final volume of 20 μL. The reactions were run in 3 or 4  
529 replicates in 384-well plates, F-bottom, μClear bottom, black, sterile, with lid (Greiner). The  
530 incubations were maintained at 37°C in the TECAN plate reader INFINITE 200 PRO Option M  
531 PLEX and the fluorescence was recorded at an initial time point and after 2 h 30 min or 3 hours.  
532 For the lateral flow assay (LFA) readout Milenia HybriDetect strips were used and the  
533 RNaseAlert probe was substituted for 10 pmol of LF-RNA reporter (/56-  
534 FAM/rUrUrUrUrU/3Bio) and was incubated likewise. Following this, the SHERLOCK  
535 reaction was mixed with 80 μL of a PEG-based CRISPR-optimized Lateral Flow Assay Buffer  
536 (provided by Milenia Biotec GmbH, Germany). The strip was dipped in the mix and the results  
537 were interpreted after 5 min.

## 538 **SHERLOCK one-step reaction**

539 For the single step SHERLOCK assay, 8 μL of input NA were mixed with 1 pellet of TwistAmp  
540 Basic kit, 20 mM HEPES pH 8, 60 mM KCl, 5% PEG-8000, 132 ng of LwCas13a in 1mM Tris-  
541 HCl pH 7.5, 12 mM NaCl, 0.1% glycerol, 125 nM of RNaseAlert probe, 2 U/μL of ProtoScript II

542 RT (NEB), 0.1 U/μL of RNase H (NEB), 1 U/μL of NxGen T7 RNA Polymerase (Biosearch  
543 technology), 455 nM of each RPA primer, 10 nM of crRNA and 14 mM of MgOAc in a final  
544 volume of 107.5 μL. For each technical replicate, 20 μL of the mix were transferred to a 384-well  
545 plate, F-bottom, μClear bottom, black, sterile, with lid (Greiner). The incubations were done in  
546 the TECAN plate reader as described above. The fluorescence was monitored over 2 h 30 min at  
547 37°C with a 30 min interval between acquisitions.

#### 548 **Quantitative PCR analysis**

549 TNA were analyzed by qPCR using Luna Universal qPCR MasterMix (NEB). The qPCR  
550 amplification mix contained 1 μL template and 0.4 μM of each primer (Tb177bp F/R). Reactions  
551 were run in triplicate in a Hard-shell PCR Plates 96 well, thin wall, which were sealed with  
552 Microseal 'B' Seals (BioRad). All experiments were run on a CFX96 Touch Real-time Detection  
553 system with a C1000 Touch Thermal cycler (Bio-Rad), using the following PCR cycling  
554 conditions: 50°C for 5 min, 95°C for 10 min, then 40 cycles of 95°C for 15 sec and 66°C for  
555 1 min (fluorescence intensity data collected at the end of the last step), followed by a  
556 temperature gradient between 66°C and 95°C. The last step was used for dissociation analysis of  
557 the PCR product to monitor the amplicon identity. For that, the melt temperature of the amplicons  
558 from clinical samples was compared with that from *T. brucei* control nucleic acids. Sequence of  
559 primers in this section are listed in supplementary table 6.

#### 560 **Data analysis**

561 We used the fluorescence given by the negative control, where water is used as input material, as  
562 the background fluorescence. To calculate the background-subtracted fluorescence intensities in a  
563 given multi-well plate, we subtracted the background fluorescence from each sample fluorescence  
564 at final time point. To calculate the fold-change over background fluorescence in a given multi-  
565 well plate, sample fluorescence was divided by background fluorescence at final time point. For  
566 the optimization of the TNA extraction methods, fluorescence values were reported as fold-  
567 changes from the initial baseline fluorescence intensity by dividing the fluorescence value at last  
568 time point by the value at initial time point. Baseline initial fluorescence and background  
569 fluorescence differ between runs. Therefore, it was more effective to compare fold-change over  
570 background fluorescence.

571 For the analysis of the clinical samples the following ratios were calculated for every target  
572 assessed:

- 573 • Negative template controls Ratio ( $R_{ntc}$ ) = Fold-change over the initial baseline  
574 fluorescence:

$$R_{ntc} = \frac{FC_{ntc} t = 3h}{FC_{ntc} t = 0}$$

Mean  $R_{ntc}$  = mean  $R_{ntc}$  of 3 replicates

575 Where FC, fluorescence readout

- 576 • Positive template controls Ratio ( $R_{pc}$ ) and sample Ratio ( $R_{sample}$ ) = Fold-change over  
577 the background fluorescence at time 3h. Background fluorescence is given by the negative  
578 template control reaction:

$$R_{pc} = \frac{FC_{pc\ t = 3h}}{FC_{ntc\ mean\ t = 3h}}$$

Mean  $R_{pc}$  = mean  $R_{pc}$  of 3 replicates

$$R_{sample} = \frac{FC_{sample\ t = 3h}}{FC_{ntc\ mean\ t = 3h}}$$

Mean  $R_{sample}$  = mean  $R_{sample}$  of 3 replicates

579 Where FC, fluorescence readout

580 Fluorescence ratios from positive and negative samples were computed by receiver operating  
581 characteristic (ROC) curve analysis for determining test positivity thresholds (fig. S11).

582 For qPCR, mean Ct values of 3 technical replicates were reported. A read was considered positive  
583 when the Ct value was lower than the established cut-off and the identity of the amplicon of these  
584 assays was confirmed by dissociation analysis (specific melt temperature  $\pm$  0.5 degrees). The  
585 specific melt temperature for each amplicon was calculated by dissociation analysis of the qPCR  
586 amplicons using dilution series of TNA from cultured parasites. The Ct value cut-off was  
587 determined using cumulative distribution analysis (fig. S12).

588 All plots and statistical analyses were performed with GraphPad Prism 9.1.2.

## 589 Acknowledgments

590 We would like to thank the following people for kindly providing parasite strains and / or parasite  
591 NAs used in this study: Annette MacLeod (University of Glasgow, Glasgow, UK), Gerald Spaeth  
592 and Artur Scherf (Institut Pasteur, Paris, France), Philippe Büscher and Nick Van Reet (Institute  
593 of Tropical Medicine, Antwerp, Belgium).

594 **Funding:** This project has received a funding from the Institut Pasteur to BR and LG (PTR-175  
595 SHERLOCK4HAT) and from the French Government's Investissement d'Avenir program  
596 Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (LabEx IBEID).  
597 NS was supported by funding from the Institut Pasteur (PTR-175 SHERLOCK4HAT). The  
598 funders had no role in study design, data collection and analysis, decision to publish, or  
599 preparation of the manuscript.

500 **Author contributions:** NS, BR and LG conceived and designed the experiments. NS, ADH  
501 performed the experiments. NS, BR and LG analyzed the data. MNU, BLP, BR and LG  
502 contributed reagents, materials and analysis tools. NS, BR and LG wrote the paper.

503 **Competing interests:** The authors declare that they have no competing interests.



504 **Data and materials availability:** All data are available in the main text or the supplementary  
505 materials.

506

507 **Ethics statement:** Blood from healthy human donors was provided by ICAREB platform  
508 (Clinical Investigation & Access to Research Bioresources) in the Center for Translational  
509 Science, at the Institut Pasteur (Paris). All participants gave written informed consent in the frame  
510 of the healthy volunteers Diagnicoll cohort (Clinical trials NCT 03912246) after approval of the  
511 CPP Ile-de-France I Ethics Committee (2009, April 30th). For the WHO HAT Specimen  
512 biobank samples, approval was given by the WHO Ethical Review Committee, each national  
513 ethical committee where samples were taken and the national Ministries of Health.

514

## 515 **References**

- 516 1. P. Büscher, G. Cecchi, V. Jamonneau, G. Priotto, Human African trypanosomiasis. *The*  
517 *Lancet*. **390**, 2397–2409 (2017).
- 518 2. J. R. Franco, G. Cecchi, G. Priotto, M. Paone, A. Diarra, L. Grout, P. P. Simarro, W. Zhao,  
519 D. Argaw, Monitoring the elimination of human African trypanosomiasis at continental  
520 and country level: Update to 2018. *Plos Negl Trop Dis*. **14**, e8261 (2020).
- 521 3. P. Büscher, S. Deborggraeve, How can molecular diagnostics contribute to the elimination  
522 of human African trypanosomiasis? *Expert Rev Mol Diagn*. **15**, 607-615 (2015).
- 523 4. S. Deborggraeve, P. Büscher, Recent progress in molecular diagnosis of sleeping sickness.  
524 *Expert Rev Mol Diagn*. **12**, 719–730 (2012).
- 525 5. M. Camara, A. M’mah Soumah, H. Ilboudo, C. Travaillé, C. Clucas, A. Cooper, N.-R. K.  
526 Swar, O. Camara, I. Sadissou, E. Calvo Alvarez, A. Crouzols, J.-M. Bart, V. Jamonneau,  
527 M. Camara, A. Macleod, B. Bucheton, B. Rotureau, Extravascular dermal trypanosomes in  
528 suspected and confirmed cases of gambiense human African trypanosomiasis. *Clinical*  
529 *Infectious Diseases*. **73**, 12–20 (2021).
- 530 6. P. Capewell, K. Atkins, W. Weir, V. Jamonneau, M. Camara, C. Clucas, N.-R. K. Swar, D.  
531 M. Ngoyi, B. Rotureau, P. Garside, A. P. Galvani, B. Bucheton, A. Macleod, Resolving the  
532 apparent transmission paradox of African sleeping sickness. *Plos Biol*. **17**, e3000105  
533 (2019).
- 534 7. M. Aliee, M. J. Keeling, K. S. Rock, Modelling to explore the potential impact of  
535 asymptomatic human infections on transmission and dynamics of African sleeping  
536 sickness. *PLoS Comput Biol*. **17**, e1009367 (2021).
- 537 8. R. A. Lee, H. de Puig, P. Q. Nguyen, N. M. Angenent-Mari, N. M. Donghia, J. P. Mcgee,  
538 J. D. Dvorin, C. M. Klapperich, N. R. Pollock, J. J. Collins, Ultrasensitive CRISPR-based  
539 diagnostic for field-applicable detection of Plasmodium species in symptomatic and  
540 asymptomatic malaria. *PNAS*. **41**, 25722-25731 (2020).
- 541 9. C. H. Cunningham, C. M. Hennelly, J. T. Lin, R. Ubalee, R. M. Boyce, E. M. Mulogo, N.  
542 Hathaway, K. L. Thwai, F. Phanzu, A. Kalonji, K. Mwandagalirwa, A. Tshetu, J. J.  
543 Juliano, J. B. Parr, A novel CRISPR-based malaria diagnostic capable of Plasmodium  
544 detection, species differentiation, and drug-resistance genotyping. *EBioMedicine*. **68**,  
545 e103415 (2021).
- 546 10. M. M. Kaminski, O. O. Abudayyeh, J. S. Gootenberg, F. Zhang, J. J. Collins, CRISPR-  
547 based diagnostics. *Nature Biomedical Engineering*. **5**, 643–656 (2021).
- 548 11. J. S. Gootenberg, O. O. Abudayyeh, J. W. Lee, P. Essletzbichler, A. J. Dy, J. Joung, V.  
549 Verdine, N. Donghia, N. M. Daringer, C. A. Freije, C. Myhrvold, R. P. Bhattacharyya, J.

- 550 Livny, A. Regev, E. V. Koonin, D. T. Hung, P. C. Sabeti, J. J. Collins, F. Zhang, Nucleic  
551 acid detection with CRISPR-Cas13a/C2c2. *Science*. **356**, 438–442 (2017).
- 552 12. J. S. Gootenberg, O. O. Abudayyeh, M. J. Kellner, J. Joung, J. J. Collins, F. Zhang,  
553 Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6.  
554 *Science*. **360**, 439–444 (2018).
- 555 13. M. J. Kellner, J. G. Koob, J. S. Gootenberg, O. O. Abudayyeh, F. Zhang, SHERLOCK:  
556 nucleic acid detection with CRISPR nucleases. *Nature Protocols*. **14**, 2986–3012 (2019).
- 557 14. A. Tambe, A. East-Seletsky, G. J. Knott, J. A. Doudna, M. R. O’Connell, RNA binding  
558 and HEPN-nuclease activation are decoupled in CRISPR-Cas13a. *Cell Reports*. **24**, 1025–  
559 1036 (2018).
- 560 15. M. Berberof, D. Pérez-Morga, E. Pays, A receptor-like flagellar pocket glycoprotein  
561 specific to *Trypanosoma brucei gambiense*. *Mol Biochem Parasitol*. **113**, 127-138 (2001).
- 562 16. W. Gibson, L. Nemetschke, J. Ndung’u, Conserved sequence of the TgsGP gene in Group  
563 1 *Trypanosoma brucei gambiense*. *Infect Genet Evol*. **10**, 453–458 (2010).
- 564 17. C. Felu, J. Pasture, E. Pays, D. Pérez-Morga, Diagnostic potential of a conserved genomic  
565 rearrangement in the *trypanosoma brucei gambiense*-specific TgSGP locus. *Am J Trop*  
566 *Med Hyg*. **76**, 922–929 (2007).
- 567 18. C. de Greef, R. Hamers, The serum resistance-associated (SRA) gene of *Trypanosoma*  
568 *brucei rhodesiense* encodes a variant surface glycoprotein-like protein. *Mol Biochem*  
569 *Parasitol*. **68**, 277–284 (1994).
- 570 19. C. de Greef, H. Imberechts, G. Matthyssens, N. Van Meirvenne, R. Hamers, A gene  
571 expressed only in serum-resistant variants of *Trypanosoma brucei rhodesiense*. *Mol*  
572 *Biochem Parasitol*. **36**, 169-176 (1989).
- 573 20. S. C. Welburn, K. Picozzi, E. M. Fèvre, P. G. Coleman, M. Odiit, M. Carrington, I.  
574 Maudlin, Identification of human-infective trypanosomes in animal reservoir of sleeping  
575 sickness in Uganda by means of serum-resistance-associated (SRA) gene. *The Lancet*. **358**,  
576 2017–2019 (2001).
- 577 21. M. Radwanska, M. Chamekh, L. Vanhamme, F. Claes, S. Magez, E. Magnus, P. de  
578 Baetselier, P. Büscher, E. Pays, The serum resistance-associated gene as a diagnostic tool  
579 for the detection of *Trypanosoma brucei rhodesiense*. *Am J Trop Med Hyg*. **67**, 684–690  
580 (2002).
- 581 22. W. Gibson, T. Backhouse, A. Griffiths, The human serum resistance associated gene is  
582 ubiquitous and conserved in *Trypanosoma brucei rhodesiense* throughout East Africa. *Inf*  
583 *Genet Evol*. **1**, 207-214 (2002).
- 584 23. O. Balmer, J. S. Beadell, W. Gibson, A. Caccone, Phylogeography and taxonomy of  
585 *Trypanosoma brucei*. *PLoS Negl Trop Dis*. **5**, e961 (2011).
- 586 24. H. Van Xong, L. Vanhamme, M. Chamekh, C. E. Chimfwembe, J. Van Den Abbeele, A.  
587 Pays, N. Van Meirvenne, R. Hamers, P. de Baetselier, E. Pays, A VSG expression site-  
588 associated gene confers resistance to human serum in *Trypanosoma rhodesiense*. *Cell*. **95**,  
589 839–846 (1998).
- 590 25. L. Vanhamme, H. Renauld, L. Lecordier, P. Poelvoorde, J. Van Den Abbeele, E. Pays, The  
591 *Trypanosoma brucei* reference strain TREU927/4 contains *T. brucei rhodesiense*-specific  
592 SRA sequences, but displays a distinct phenotype of relative resistance to human serum.  
593 *Mol Biochem Parasitol*. **135**, 39–47 (2004).
- 594 26. J. D. Milner, S. L. Hajduk, Expression and localization of serum resistance associated  
595 protein in *Trypanosoma brucei rhodesiense*. *Mol Biochem Parasitol*. **104**, 271–283 (1999).
- 596 27. M. Camara, O. Camara, H. Ilboudo, H. Sakande, J. Kaboré, L. N’Dri, V. Jamonneau, B.  
597 Bucheton, Sleeping sickness diagnosis: Use of buffy coats improves the sensitivity of the  
598 mini anion exchange centrifugation test. *Tropical Medicine and International Health*. **15**,  
599 796–799 (2010).

- 700 28. P. Büscher, D. M. Ngoyi, J. Kaboré, V. Lejon, J. Robays, V. Jamonneau, N. Bebronne, W.  
701 Van Der Veken, S. Biéler, Improved models of mini anion exchange centrifugation  
702 technique (mAECT) and modified single centrifugation (MSC) for sleeping sickness  
703 diagnosis and staging. *PLoS Negl Trop Dis.* **3**, e471 (2009).
- 704 29. D. R. Moser, G. A. Cook, D. E. Ochs, C. P. Bailey, M. R. McKane, J. E. Donelson,  
705 Detection of trypanosoma congolense and trypanosoma brucei subspecies by DNA  
706 amplification using the polymerase chain reaction. *Parasitology.* **99**, 57–66 (1989).
- 707 30. P. Mitashi, E. Hasker, D. M. Ngoyi, P. P. Pyana, V. Lejon, W. Van der Veken, P. Lutumba,  
708 P. Büscher, M. Boelaert, S. Deborggraeve, Diagnostic accuracy of loopamp Trypanosoma  
709 brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples.  
710 *PLoS Negl Trop Dis.* **7**, e2504 (2013).
- 711 31. C. F. Alfred Compaoré, H. Ilboudo, J. Kaboré, J. W. Kaboré, O. Camara, M. Bamba, H.  
712 Sakande, M. Koné, M. Camara, D. Kaba, A. M. Gaston Belem, S. Deborggraeve, P.  
713 Büscher, B. Bucheton, V. Lejon, V. Jamonneau, Analytical sensitivity of loopamp and  
714 quantitative real-time PCR on dried blood spots and their potential role in monitoring  
715 human African trypanosomiasis elimination. *Experimental Parasitology.* **219**, e108014  
716 (2020).
- 717 32. S. Becker, J. R. Franco, P. P. Simarro, A. Stich, P. M. Abel, D. Steverding, Real-time PCR  
718 for detection of Trypanosoma brucei in human blood samples. *Diagn Microbiol Infect Dis.*  
719 **50**, 193–199 (2004).
- 720 33. C. M. Mugasa, T. Laurent, G. J. Schoone, P. A. Kager, G. W. Lubega, H. D. F. H. Schallig,  
721 Nucleic acid sequence-based amplification with oligochromatography for detection of  
722 Trypanosoma brucei in clinical samples. *Journal of Clinical Microbiology.* **47**, 630–635  
723 (2009).
- 724 34. P. González-Andrade, M. Camara, H. Ilboudo, B. Bucheton, V. Jamonneau, S.  
725 Deborggraeve, Diagnosis of trypanosomatid Infections; targeting the spliced leader RNA. *J*  
726 *Mol Diagn.* **16**, 400–404 (2014).
- 727 35. S. Deborggraeve, V. Lejon, R. A. Ekangu, D. M. Ngoyi, P. P. Pyana, M. Dard Ilunga, J. P.  
728 Mulunda, P. Büscher, Diagnostic accuracy of PCR in gambiense sleeping sickness  
729 diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study. *Plos Negl*  
730 *Trop Dis.* **5**, e972 (2011).
- 731 36. M. Radwanska, P. Claes, S. Magez, E. Magnus, D. Pérez-Morga, E. Pays, P. Büscher,  
732 Novel primer sequences for Polymerase Chain Reaction-based detection of Trypanosoma  
733 brucei gambiense. *Am J Trop Med Hyg.* **67**, 289–295 (2002).
- 734 37. Z. K. Njiru, A. S. J. Mikosza, T. Armstrong, J. C. Enyaru, J. M. Ndung’u, A. R. C.  
735 Thompson, Loop-mediated isothermal amplification (LAMP) method for rapid detection of  
736 Trypanosoma brucei rhodesiense. *PLoS Negl Trop Dis.* **2**, e147 (2008).
- 737 38. J. Arizti-Sanz, C. A. Freije, A. C. Stanton, B. A. Petros, C. K. Boehm, S. Siddiqui, B. M.  
738 Shaw, G. Adams, T. S. F. Kosoko-Thoroddsen, M. E. Kembal, J. N. Uwanibe, F. V.  
739 Ajogbasile, P. E. Eromon, R. Gross, L. Wronka, K. Caviness, L. E. Hensley, N. H.  
740 Bergman, B. L. MacInnis, C. T. Happi, J. E. Lemieux, P. C. Sabeti, C. Myhrvold,  
741 Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2.  
742 *Nature Communications.* **11**, 5921 (2020).
- 743 39. O. O. Abudayyeh, J. S. Gootenberg, S. Konermann, J. Joung, I. M. Slaymaker, D. B. T.  
744 Cox, S. Shmakov, K. S. Makarova, E. Semenova, L. Minakhin, K. Severinov, A. Regev, E.  
745 S. Lander, E. V. Koonin, F. Zhang, C2c2 is a single-component programmable RNA-  
746 guided RNA-targeting CRISPR effector. *Science.* **353**, aaf5573 (2016).
- 747 40. N. Van Reet, P. Patient Pyana, S. Dehou, N. Bebronne, S. Deborggraeve, P. Büscher,  
748 Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei

749 repeat (TBR) sequence can be used to enhance amplification and genotyping of  
750 Trypanozoon strains. *PLOS ONE*. **16**, e0258711 (2021).

- 751 41. J. R. Franco, P. P. Simarro, A. Diarra, J. A. Ruiz-Postigo, J. G. Jannin, The human African  
752 trypanosomiasis specimen biobank: A necessary tool to support research of new  
753 diagnostics. *PLoS Negl Trop Dis*. **6**, e1571 (2012).
- 754 42. S. Deborggraeve, F. Claes, T. Laurent, P. Mertens, T. Leclipteux, J. C. Dujardin, P.  
755 Herdewijn, P. Büscher, Molecular dipstick test for diagnosis of sleeping sickness. *Journal*  
756 *of clinical microbiology*. **44**, 2884–2889 (2006).
- 757 43. C. M. Mugasa, G. J. Schoone, R. A. Ekangu, G. W. Lubega, P. A. Kager, H. D. F. H.  
758 Schallig, Detection of *Trypanosoma brucei* parasites in blood samples using real-time  
759 nucleic acid sequence-based amplification. *Diagn Microbiol Infect Dis*. **61**, 440–445  
760 (2008).
- 761 44. Z. K. Njiru, A. S. J. Mikosza, E. Matovu, J. C. K. Enyaru, J. O. Ouma, S. N. Kibona, R. C.  
762 A. Thompson, J. M. Ndung’u, African trypanosomiasis: Sensitive and rapid detection of  
763 the sub-genus Trypanozoon by loop-mediated isothermal amplification (LAMP) of parasite  
764 DNA. *International Journal for Parasitology*. **38**, 589–599 (2008).
- 765 45. K. Picozzi, E. M. Fèvre, M. Odiit, M. Carrington, M. C. Eisler, I. Maudlin, S. C. Welburn,  
766 Sleeping sickness in Uganda: A thin line between two fatal diseases. *British Medical*  
767 *Journal*. **331**, 1238–1241 (2005).
- 768 46. J. So, *et al.*, <https://doi.org/10.1101/2021.09.09.459620> (2021).
- 769 47. C. Myhrvold, C. A. Freije, J. S. Gootenberg, O. O. Abudayyeh, H. C. Metsky, A. F.  
770 Durbin, M. J. Kellner, A. L. Tan, L. M. Paul, L. A. Parham, K. F. Garcia, K. G. Barnes, B.  
771 Chak, A. Mondini, M. L. Nogueira, S. Isern, S. F. Michael, I. Lorenzana, N. L. Yozwiak,  
772 B. L. MacInnis, I. Bosch, L. Gehrke, F. Zhang, P. C. Sabeti, Field-deployable viral  
773 diagnostics using CRISPR-Cas13. *Science*. **320**, 444-448 (2018).
- 774 48. J. Joung, A. Ladha, M. Saito, N.-G. Kim, A. E. Woolley, M. Segel, R. P. J. Barretto, A.  
775 Ranu, R. K. Macrae, G. Faure, E. I. Ioannidi, R. N. Krajeski, R. Bruneau, M.-L. W. Huang,  
776 X. G. Yu, J. Z. Li, B. D. Walker, D. T. Hung, A. L. Greninger, K. R. Jerome, J. S.  
777 Gootenberg, O. O. Abudayyed, F. Zhang, Detection of SARS-CoV-2 with SHERLOCK  
778 one-pot testing. *N Engl J Med*. **383**, 14992-1494 (2020).
- 779 49. J. Dunlop, C. K. Thompson, S. S. Godfrey, R. C. A. Thompson, Sensitivity testing of  
780 trypanosome detection by PCR from whole blood samples using manual and automated  
781 DNA extraction methods. *Experimental Parasitology*. **146**, 20–24 (2014).
- 782 50. W. Weir, P. Capewell, B. Foth, C. Clucas, A. Pountain, P. Steketee, N. Veitch, M. Koffi, T.  
783 De Meeû, J. Kaboré, M. Camara, A. Cooper, A. Tait, V. Jamonneau, B. Bucheton, M.  
784 Berriman, A. MacLeod, Population genomics reveals the origin and asexual evolution of  
785 human infective trypanosomes. *eLIFE*. **5**, e11473 (2015).
- 786 51. P. Esterre, A. Ait-Saadi, L. Arowas, S. Chaouche, N. Corre-Catelin, C. Fanaud, H. Laude,  
787 V. Mellon, V. Monceaux, G. Morizot, I. Najjar, C. Ottone, B. L. Perlaza, B. Rimbault, L.  
788 Sangari, M. N. Ungeheuer, The ICAReB Platform: A human biobank for the Institut  
789 Pasteur and beyond. *Open Journal of Bioresources*. **7**, 1 (2020) BB-0033-00062, BBMRI  
790 A0203/ 21 distributions/ last access: 2021, 06, 29.

## 796 Figure Legends

797  
798 **Fig. 1. Detection of *Trypanosoma brucei* sspp. RNA with SHERLOCK. (A), Schematic**

799 overview of the SHERLOCK assay principle. Two-step SHERLOCK reaction is performed after  
800 TNA extraction. First, target NA is retro-transcribed and/or amplified during the RT/RPA  
801 reaction at 42°C. Second, the amplified target is *in vitro* transcribed and detected by Cas13a that  
802 cuts the RNA reporter upon target activation. Finally, the released reporter can be quantified with  
803 a fluorescence plate reader and / or with a LFA, making the methodology suitable for both mass  
804 screening and PoC testing. Panel created using BioRender.com. (B), Schematic showing selected  
805 target genes, RPA primer pairs and CRISPR guides. (C), Specificity of *7SLRNA*, *TgSGP* and *SRA*  
806 in a two-step SHERLOCK reaction using RNA from *T. b. brucei* Lister 427, *T. b. gambiense*  
807 ELIANE strain, *T. b. rhodesiense* EATRO strain, *Plasmodium falciparum*, *Leishmania major* and  
808 Human Embryonic Kidney (HEK) T cells. Fluorescence was measured after 150 mins.  
809 Background subtracted fluorescence of 4 technical replicates is plotted as mean +/- standard  
810 deviation (SD). a.u., arbitrary units. (D), Limits of detection of the *7SLRNA*, *TgSGP* and *SRA*  
811 targets in two-step SHERLOCK reactions. Dilution series of total RNA extracted from cultured  
812 parasites. *T. b. brucei* Lister 427, *T. b. gambiense* ELIANE strain, *T. b. rhodesiense* EATRO  
813 strain were used for the *7SLRNA*, *TgSGP* and *SRA* SHERLOCK reactions, respectively.  
814 Fluorescence was measured after 150 mins. Coloured circles represent the mean  $\pm$  SD of 4  
815 technical replicates. Two-tailed Student's t test between fluorescence outputs of sample vs. no-  
816 template control. \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . a.u., arbitrary units. ns, non-significant. (E), Limit  
817 of detection of *7SLRNA*, *TgSGP* and *SRA* in a two-step SHERLOCK reaction with a lateral flow  
818 assay (LFA) read-out after 5 mins. (F), Limits of detection of two-step vs. single-step *7SLRNA*  
819 SHERLOCK reactions on total RNAs from *T. b. brucei* Lister 427. Fluorescence was measured  
820 after 150 mins. Blue bars represent the mean background subtracted fluorescence  $\pm$  SD of 4  
821 technical replicates shown as open circles. a.u., arbitrary units. (G), Kinetics of the single step  
822 reaction in F. Each coloured circle represents the average of 4 technical replicates  $\pm$  SD. Two-  
823 tailed Student's t test between fluorescence outputs of sample vs. no-template control. \*\*\*  
824  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . a.u., arbitrary units. ns, non-significant.

825  
826

827 **Fig. 2. Validation of SHERLOCK4HAT using field isolated samples.** SHERLOCK detection  
828 of *7SLRNA*, *TgSGP* or *SRA* targets using RNA extracted from field isolated trypanosome strains.  
829 *TgSGP* (left panel) and *SRA* (right panel) target readouts are plotted against *7SLRNA* readouts in  
830 fold change over background fluorescence. Each dot represents the average readout of 4 technical  
831 replicates. The thresholds for each target (red lines) were determined using ROC curve analyses  
832 of positive and negative sample data. In brackets, after the name of the species, number of strains  
833 analysed.

834  
835

836 **Fig. 3. Performance of SHERLOCK4HAT on dried blood spots, whole blood and buffy coat.**

837 (A), A comparison of the performance of the *7SLRNA* SHERLOCK on trypanosome RNA  
838 extracted from dried blood spots (DBS), whole blood and buffy coat. All experiments were done  
839 in 4 replicates from a single pool of simulated infected blood. Fold changes over background  
840 fluorescence were plotted as mean +/- SD. Student's two-tailed t test between readout of sample  
841 vs. no-template control. \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . (B), Samples with known parasitemia were  
842 used to assess the analytical sensitivity of the *7SLRNA* SHERLOCK. Three replicates of each  
843 dilution were tested. The tentative limit of detection (LoD) was the lowest concentration where  
844 3/3 replicates were positive for the test. The detection threshold (red line) was determined using  
845 ROC curve analyses of positive and negative sample data. (C), The LoD was confirmed by using  
846 samples at 0.66X, 1X and 1.5X the estimated LoD concentration of the buffy coat only. The

347 experiment was done on 20 replicates and the LoD was determined to be the concentration at  
348 which 95% of the samples were positive for the test. The detection threshold (red line) was  
349 determined using ROC curve analyses of positive and negative sample data. **(D)**, Tables  
350 summarizing the results in panels B and C. Performance near the LoD of *7SLRNA* SHERLOCK  
351 with whole blood and buffy coat samples.

352


353 **Fig. 4. Validation of SHERLOCK4HAT diagnostic using bio-banked clinical samples. (A),**  
354 *7SLRNA*

355 SHERLOCK analysis of 160 gHAT qPCR positive (left) and negative (right) buffy coat samples  
356 obtained from human subjects in gHAT endemic and non-endemic regions. Each dot indicates one  
357 sample analysed by both *7SLRNA* SHERLOCK and *Tb177bp-repeats*-qPCR. The dashed red line  
358 is the threshold above which samples were considered positive for SHERLOCK. The dot colours  
359 indicate the classification according to the original diagnosis in the field. **(B)**, Concordance tables,  
360 sensitivity and specificity of *7SLRNA* SHERLOCK for detection of trypanosome NA in buffy coat  
361 samples from individuals in gHAT endemic and non-endemic regions. qPCR indicates samples  
362 that were analysed by *Tb177bp-repeats*-qPCR. nC, negative controls from non-endemic regions,  
363 gC, gHAT negative endemic controls. **(C)**, *7SLRNA* SHERLOCK analysis of 53 rHAT qPCR  
364 positive (left) and negative (right) buffy coat samples obtained from human subjects in rHAT  
365 endemic and non-endemic regions. Each dot indicates one sample analysed by both *7SLRNA*  
366 SHERLOCK and *Tb177bp-repeats*-qPCR. The dashed red line is the threshold above which  
367 samples were considered positive for SHERLOCK. The dot colours indicate the classification  
368 according to the original diagnostic in the field. **(D)**, Concordance tables, sensitivity and  
369 specificity of *7SLRNA* SHERLOCK for detection of trypanosome NA in buffy coat samples from  
370 individuals in rHAT endemic and non-endemic regions. qPCR indicates samples that were  
371 analysed by *Tb177bp-repeats*-qPCR. nC, non-endemic negative controls, rC, rHAT endemic  
372 negative controls. **(E)**, *TgSGP* and *SRA* SHERLOCK discriminate between *T. b. gambiense* and *T.*  
373 *b. rhodesiense* NA in patients. All gHAT and rHAT patient samples positive for *7SLRNA* were  
374 plotted according to their *TgSGP* and *SRA* SHERLOCK results. The thresholds for each target (red  
375 lines) were determined using ROC curve analyses of positive and negative sample data.

376

377 **Table 1. RPA primers and crRNA guides selected in this study.**

378



# Figure 2

Fold change over background fluorescence








Figure 3



# Figure 4

A

## Samples from gHAT patients



B

### Samples from gHAT patients: SHERLOCK vs qPCR


7SLRNA SHERLOCK	Positive for qPCR	Negative for qPCR	Total	Concordance	Sensitivity
Positive	40	16	56	40+97/160 (85.6%)	40/47 (85.1%)
Negative	7	97	104		
Total	47	113	160		

### Samples from gHAT patients: SHERLOCK vs field diagnosis

7SLRNA SHERLOCK	nC	gC	gHAT stage 1	gHAT stage 2	Total	Concordance	Specificity
Positive	1	0	27	28	56	13+48+27+28/160 (72.5%)	
Negative	13	48	23	20	104		13+48/14+48 (98.4%)
Total	14	48	50	48	160		

C

## Samples from rHAT patients



D


### Samples from rHAT patients: SHERLOCK vs qPCR

7SLRNA SHERLOCK	Positive for qPCR	Negative for qPCR	Total	Concordance	Sensitivity
Positive	19	2	21	32+19/53 (96.2%)	19/19 (100%)
Negative	0	32	32		
Total	19	34	53		

### Samples from rHAT patients: SHERLOCK vs field diagnosis

7SLRNA SHERLOCK	nC	rC	rHAT stage 2	Total	Concordance	Specificity
Positive	1	1	19	21	13+19+19/53 (96.2%)	
Negative	13	19	0	32		13+19/14+20 (94.1%)
Total	14	20	19	53		

E



Trypanosoma species Target (accession number)	RPA forward primer with <i>T7 promoter overhang 5'&gt;3'</i>	RPA reverse primer 5'>3'	crRNA sequence 5'>3' (DR + spacer 28nt)
<i>Trypanozoon</i> 7SLRNA (Tb927.8.2861)	GAAATTAATACGACTCACTATAGG GCGGAGCGCATTGCTCTGTAACC TTC	CCACTTTAACGGCGC GAGAACGCC	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACCAACACCGACACGCAACC AAGCAGAACA
<i>T. brucei gambiense</i> TgSGP (FN555988.1)	GAAATTAATACGACTCACTATAGG GTTT GACAGCATGGGAGATGCAACTC GCAAG	CAAGTCCGTGACAGC CTTGCCCGTTCCCGC	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACAAAUGGCUUCCAGCUUCC GCUGUGCUAG
<i>T. brucei rhodesiense</i> SRA (AF097331)	GAAATTAATACGACTCACTATAGG GAA AAGCAAACCTCGTATCAATCCAA GAGT	CCCTTGTCCTTTGTCGT CGCCAATTGCGT	GAUUUAGACUACCCCAAAAACGAAGGG GACUAAAACGGCGACCUGCUGCUUGCA GCUUUCAGUG

Table 1. RPA primers and crRNAs selected in this study